Related references
Note: Only part of the references are listed.Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer
Xin Zhang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis
Yutian Zou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
J Cortés et al.
ANNALS OF ONCOLOGY (2019)
Immunotherapy: A Challenge of Breast Cancer Treatment
Marilina Garcia-Aranda et al.
CANCERS (2019)
Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer
Elham Safarzadeh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
New Strategies in Breast Cancer: Immunotherapy
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2016)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma
Takuji Torimura et al.
TRANSLATIONAL ONCOLOGY (2013)
The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors
James W. Hodge et al.
SEMINARS IN ONCOLOGY (2012)
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Giovanna Gallina et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells
AK Nowak et al.
JOURNAL OF IMMUNOLOGY (2003)
Single-agent gemcitabine is active in previously treated metastatic breast cancer
M Spielmann et al.
ONCOLOGY (2001)